|Bid||28.72 x 900|
|Ask||28.75 x 900|
|Day's Range||27.00 - 29.07|
|52 Week Range||17.30 - 73.72|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||54.45|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
Shares of Ionis Pharmaceuticals and Akcea Therapeutics popped Wednesday after the biotech companies said their high triglycerides treatment succeeded in a midstage study.
Shares of highly rated biotech company Arrowhead Pharmaceuticals crashed to a two-month low Tuesday after an analyst initiated coverage of ARWR stock with an underperform rating.
Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference. Arrowhead Pharma stock is testing key support.
Heading into the new year, only one word matters for the biotech stocks: buyout.Already, we've seen a fury of activity this past year, as many of the larger pharmaceutical and biotech giants look to plug holes in their aging pipelines. This activity accelerated at the end of the end, with Novartis (NYSE:NVS), Merck (NYSE:MRK) and Sanofi (NASDAQ:SNY) all making big blockbuster buys over the last month or so.And, the buys could continue into the new year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor one thing, many of the big biotech stocks are flushed with cash. Thanks to the tax cuts of 2017, repatriation of cash and continued sales of blockbuster drugs, many of the biggest biotech stocks are holding billions on their balance sheets. Meanwhile, pipelines and approvals of new drugs are starting to dry up. According to investment bank JPMorgan Chase (NYSE:JPM), over the last 20 years, the FDA has only approved an average of between 20 and 25 new drugs per year. Most of those approvals have come from advanced drugs, new cancer fighters and a hefty dose of biologics.With the need to fill pipelines and replace aging blockbusters, the major biotech stocks are in a bind. And that means buying their way out of these issues. * The Top 15 Stocks to Buy in 2020 For investors, this poises an interesting scenario. Plenty of gains can be had betting on the right biotech stock with a promising pipeline as the bigger fish start spending their cash. However, which biotech stocks have the promise?Here are three biotech stocks that make for great buyout targets. Biotech Stocks That Are Buyout Targets: Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock It's no secret that gene therapy has quickly become all the rage, with pharmaceutical firms trying to tackle rare and orphan diseases. And while there are a ton of new technologies that fall under this umbrella, RNA interference (RNAi) has the potential to be a real game changer.Basically, it's a mechanism that uses a "gene's own DNA sequence of gene to turn it off." With Novartis spending nearly $10 billion on RNAi buyouts in recent months, Arrowhead Pharmaceuticals (NASDAQ:ARWR) could be an intriguing stock to look at it.ARWR's sole specialty is RNAi drugs and features a big pipeline of therapies in various stages of development. These drugs include tackling aliments like liver disease, Cystic Fibrosis and cancerous tumors. So far, the biotech has been pretty successful at navigating the various phases of clinical trials. Data from many of its late-stage drugs seem very promising.However, the real reason to be excited that ARWR could be bought out is that it already counts a very deep-pocketed biotech among its development partners. Arrowhead has already cut deals with Johnson & Johnson (NYSE:JNJ) for development of treatment for chronic hepatitis B infections. The deal provides ARWR with plenty of upfront cash, development and milestone rights. However, given the rush to buyout RNAi providers, JNJ has every reason to consider snagging the firm outright.Now, Arrowhead isn't unknown at this point. In fact, the stock has surged over the last year -- especially since October. Some of that was do to the NVS buyouts in the sector. But, a lot of it was do to ARWR's own wins and progress. But, with plenty of potential and market cap of just $6 billion, Arrowhead could provide more gains in the year ahead -- buyout or not. Amarin (AMRN)Source: Shutterstock A lot has been written about Amarin (NASDAQ:AMRN). The biotech stock has been a roller coaster the last few years, going from obscurity to being on hot lists. The reason comes down to its only medicine -Vascepa.Vascepa is really just a fish oil pill. But man, is it good. Data for the drug was stellar, with patients experiencing a 20% less chance of cardiovascular death, 31% less heart attacks and 28% less strokes. All in all, Vascepa was able to reduce cardiovascular risk by 25%. With its big cache of data and FDA approval, AMRN now has a blockbuster on its hands. Patients facing cardiovascular events who are already on statins now have another line of defense to fight. With that, AMRN now predicts that it'll be able to accumulate $650 to $700 million in sales this year.So, why buyout potential? That's an easy source of bolt-on revenue with some decent growth prospects.Cardiovascular disease remains a huge threat that only continues to get worse as diet and genetics play an increasing role. Vascepa has the potential to be the next Lipitor in that fight. And that blockbuster potential makes it a great add-on for drug companies with big cardiovascular portfolios. With a market cap of only $7 billion, Amarin is a pretty easy pill to swallow for a larger biotech stock looking to boost its sagging growth potential. * 3 Oil Stocks That Are Worth Looking Into Now In the end, Vascepa could be a blockbuster and that could lead to a sale of ARMN stock. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Non-alcoholic SteatoHepatitis (NASH) remains a tough nut to crack. The progressive liver disease can destroy the organ, and is projected to become the leading cause of all liver transplants this year. For nations with fatty diets, prevalence of NASH is estimated to be as much as 20% of the total population. The problem is that most potential treatments for the disease have fallen flat.And, that could make Intercept Pharmaceuticals (NASDAQ:ICPT) the only boat in the sea.Intercept's drug Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC). PBC is very similar to NASH. This allowed ICPT to pivot the medicine and results were pretty great. So great, that ICPT recently submitted the drug for review with the FDA.Perhaps even better is that the agency granted Intercept priority review for the drug. That could lead to quicker approval time and reduce the headaches ICPT needs to get the therapy out to market.Given the potential size of NASH and the need for the drug, ICPT could be looking at a major blockbuster on it hands. And as the only man standing in the sector, that could lead to plenty of buyout activity for the stock. This is especially true as shares of the firm have slipped over the last year, but gained traction in October. With a market cap of about $4 billion, Intercept is a very digestible for many other biotech stocks.In the end, ICPT is sitting right in the sweet spot for mergers and acquisitions activity. With strong growth potential, first-mover status and a low market cap all being factors. At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post 3 Biotech Stocks to Bank on for Buyouts in 2020 appeared first on InvestorPlace.
Throughout the year's list of the best stocks of 2019, there is an undercurrent of groundbreaking products and services that shape the way we live.
When speculative stocks make big moves to the upside, the prudent thing to do is take some profits, Jim Cramer reminded viewers during Friday night's "Mad Money" program. Case in point: Arrowhead Pharmaceuticals which is up 411% in 2019 and 133% in just the past six months. Cramer said he's still a big fan of Arrowhead and its technology that silences the genes that cause disease.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
Arrowhead Pharmaceuticals announced an underwritten offer for 4 million shares late Monday, causing its stock to collapse before the close. Arrowhead is a highly rated biotech company.
Over the past 12 months, the Nasdaq Biotech Index (NBI) has kept up with the broader market, slightly outpacing the S&P 500, until the last few months.Certainly 2019 has been a bumpy ride. But it looks like the sector, especially thank to its larger firms, is finally hitting its stride. The index is rising and a growing number of mergers over the past couple years are starting to pay off.There are some amazing new technologies that are finally gaining traction on the medication side, which includes a long journey through U.S. Food and Drug Administration trials. It usually takes about 10 years and costs around $2 billion to get a drug through trials these days.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's a lot of commitment. And during that time, you need to develop a strong pipeline for future growth. * 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are either currently thriving or well positioned for buyouts that would come with big premiums. Biotech Stocks to Buy: Galapagos (GLPG)Source: Shutterstock Galapagos (NASDAQ:GLPG) is a perfect example of the new wave in biotech. It uses adenoviruses -- viruses that usually cause respiratory illnesses -- to introduce human gene sequences to help or prevent certain proteins from multiplying.The formations of proteins play a critical role in a number of diseases, including cancer. They are also key in autoimmune diseases. And GLPG focuses on the latter.It has four drugs in clinical trials currently, and two of those are in Phase 3 trials. That is encouraging, since it is usually moving into Phase 3 trials where many drugs fall short.The stock is up a whopping 94% this year as trial results are driving price, yet its trailing price-to-earnings ratio is 38. It has a $12 billion market capitalization, so it's well funded. China Biologic Products (CBPO)Source: Shutterstock China Biologic Products (NASDAQ:CBPO) is one of China's leading biotech companies. Its work isn't fancy, but it's functional. And in a population of 1.4 billion people, high-quality drugs represent a huge step forward.China is very focused on developing its pharmaceutical and healthcare industry instead of relying on the U.S or Europe to sell it medicines. But this is a huge undertaking to start from nearly scratch.CBPO is one of the first to do it. It's not making cutting-edge drugs and doing breakthrough research -- it's focused on plasma-based biopharmaceutical products. These are fundamental for treatment of immune system disorders, epidemic diseases and disaster relief. * 10 Cheap Stocks to Buy Under $10 It gained a lot of attention last year when a consortium offered nearly $4 billion for the company. Its current market cap is $4.5 billion and the stock is up 54% year-to-date. That's the kind of momentum I like to see at Growth Investor, and there's still plenty of headroom here. Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock Arrowhead Pharmaceuticals (NASDAQ:ARWR) works on novel drugs for intractable diseases. And that about sums up its focus.Right now, it has nine drugs in trials. Two of them are in Phase 3. One is for liver disease and the other for Hepatitis B. Most of its other drugs are focused on diseases affecting the liver. It also has one in trial for lung cancer and another for renal cell carcinoma.It is focused on using RNAi, or RNA interference, to prevent cells from expressing a specific gene, usually a gene linked to a disease. RNAi has been around for a long time, and ARWR has been around since 1989. But it's now coming into its own, as technologies have grown up around it.The stock is up a staggering 432% year-to-date, due to its own work and the interest that big pharma is now taking in the sector. With a $6.3 billion market cap, it would be an easy buy for a big firm looking to acquire a solid pipeline of RNAi drugs. Acadia Pharmaceuticals (ACAD)Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on central nervous system disorders. These range from schizophrenia to Parkinson's to major depressive disorder.It actually has a drug in the market. In 2016 Nuplazid was launched to help manage the hallucinations and disorientation sometimes experienced by Parkinson's patients. Second-quarter sales were $83 million, up 46% from the same quarter a year ago. That's more than $300 million a year, and growing.It has another drug that is wrapping up Phase 3 trials and is targeted at dementia-related psychosis. Yet another drug is halfway through Phase 3 trials focused on providing an adjunctive therapy for major depressive disorder.This firm isn't just about the future, it's succeeding in the market right now. And in a unique niche, no less. This niche will continue to grow as boomers age, so demographics are also on its side. That's the kind of growth potential I demand from stocks in any industry. * 9 Tantalizing Dividend Stocks for 2020 ACAD stock is up 182% year-to-date and with a $7 billion market cap, it's still the early days. Spark Therapeutics (ONCE)Source: Shutterstock Spark Therapeutics (NASDAQ:ONCE) is a gene therapy company that focuses on genetic diseases including blindness, hemophilia and neurodegenerative conditions.These can be good areas for a relatively young gene company to plant its flag, because they aren't usually filled with as much competition. That also means that during drug trials, its efficacies don't have to meet as high standards.ONCE just launched its first drug this year, Luxturna, for inherited retinal dystrophy, which ultimately leads to blindness. Sales and results have been positive. The company also has a licensing and development deal with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can keep delivering. Zai Lab (ZLAB)Source: Shutterstock Zai Lab (NASDAQ:ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That's some pretty fast growth.Part of the reason is that Incyte Pharmaceuticals (NASDAQ:INCY), maker of the rheumatoid arthritis drug Jakafi, has become an investor. This partnership allows INCY to market its drug in China and gives ZLAB access to the U.S. market. At Growth Investor, we invest with an eye on macroeconomic trends, and these are the two markets exhibiting the strongest growth.Their product lines overlap as well, which has some strategic advantages. Both have products in autoimmune diseases, and ZLAB also is doing work in cancer and infectious diseases.ZLAB has 16 drugs in Phase 3 trials, with one, Optune, ready for market in Hong Kong. Its massive pipeline is especially attractive for a firm like INCY when looking at marketing some of these in the U.S. market. * 7 Top Stocks to Buy for 2020 The stock is up 73% year-to-date and could be a sleeping giant, if all unfolds according to plan. Natera (NTRA)Source: Shutterstock Natera (NASDAQ:NTRA) isn't a typical biotech in the sense that it develops drugs.Its niche is genetic testing. While you may think that begins and ends with prenatal testing for hereditary disorders and the like, the fact is, that's just the beginning.It can run testing on cancers so that oncologists can get an exact description of the cancer. Today, there are gene therapies and immuno-oncology therapies that can be used to help certain cancer patients. And that list is growing. Also, recurrence monitoring and treatment monitoring are much more targeted and accurate.Also, genetic testing can help make sure that transplants are more successful. For insurers and hospitals (as well as patients of course), a clean transplant means no issues with tissue rejection, infection or longer hospital stays.It might not have a sexy silver bullet in this sector, but it does have a great reputation.The stock is up 155% year-to-date. And given the lack of drama in the stock, its big growth could keep on going as long as the population continues to gray.All this gives you an idea of why these stocks rate so highly in my Portfolio Grader tool. And I've got more where that came from. There's a bigger, deeper tech trend going on that I'm even more excited about. 'The Mother of All Technologies'Up until now, technologies have certainly made our lives easier and more efficient … but with a lot of room for human error. People trip over cords, spill their coffee and get tired.Artificial intelligence does not.If that sounds futuristic, well then, the future is already here. If you use apps like Netflix (NASDAQ:NFLX), TurboTax, QuickBooks, Zillow (NASDAQ:Z) or even an email spam filter, then AI is already helping your day run more smoothly. And as scientists find even more applications for artificial intelligence -- from healthcare to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system.So any one company that can help with customers' data issues is the one company that's most worth investing in.You don't need to be an expert to take part. I'll tell you everything you need to know, as well as my "buy" recommendation, in Growth Investor. My No. 1 stock for the AI trend is still under my buy limit price -- so you'll want to sign up now. Get in while it's still cheap.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 7 Exciting Biotech Stocks to Buy Now appeared first on InvestorPlace.
Arrowhead Pharmaceuticals grabbed an upgrade Friday as ARWR stock has rocketed 159% since October on enthusiasm for the biotech company's RNAi platform. ARWR stock is 98% above a buy point.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
Shareholders will be ecstatic, with their stake up 34% over the past week following Arrowhead Pharmaceuticals, Inc.'s...